Daniel Chancellor
Therapeutic Area Director
Therapeutic Area Director
+10 year(s) experience
He stays abreast of market developments, generating and curating data sources, and distilling these into reports that enable clients to gain a competitive edge.
Since joining Pharma Intelligence in 2010, Daniel has tracked and forecast all the leading neurology, psychiatry, and pain drug markets. He is particularly interested in the shifting landscape of the multiple sclerosis market well as the implications of trial failures – alongside the successes in Alzheimer's disease R&D.
He has helped expand research and insight on rare diseases , including established orphan drug markets as well as as emerging opportunities. He also attends international medical conferences and enjoys collaborating with colleagues at Scrip.
Daniel has a First Class degree in Natural Sciences from the University of Bath.
16 Apr 2020 , 16:00
USA
Webinar
Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Scrip: 世界の医療用医薬品＆製薬...
The tumor-agnostic developer’s toolkit
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...
With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target
Topic biopharmaceutical drug-review
Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Pharmaprojects: 医薬品...
In previous years, delegates at the American Society for Clinical Oncology (ASCO) annual meeting had been treated to exciting clinical data from anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies such as Kymriah (tisagenlecleucel; Novartis), Yescarta (axicabtagene ciloleucel; Gilead), and various pipeline assets in advanced hematologic malignancies.
Topic cancer cell-and-gene-therapy
Strategic Transactions
PharmAI – industry is smartening up to the potential of artificial intelligence
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
Alkermes has announced the failure of two of its pivotal trials for its novel opioid-targeting antidepressant ALKS 5461 (buprenorphine/samidorphan), yet is emboldened by an efficacy signal
Topic alkermes
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
Entering a established market as a new player can be daunting. It's difficult to know exactly where you should be targeting your trial, and also who you should be targeting your treatment at.
Topic Parkinsons disease
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
Download your free infographic using the adjacent form. Get to grips with early-phase opportunities in our depression pipeline with our latest infographic.
In Vivo: 医療用医薬品・医療機器...
03 Feb 2020
Scrip: 世界の医療用医薬品＆製薬産...
26 Jan 2016